Alexion Can't Halt Amgen, Samsung Selling Soliris Biosimilars
A Unified Patent Court appeals panel has rejected Alexion's bid to stop Amgen and Samsung Bioepis selling biosimilar versions of Soliris in Europe, ruling that Alexion's patent over the blood disease...To view the full article, register now.
Already a subscriber? Click here to view full article